These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

424 related items for PubMed ID: 34153117

  • 21. Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study.
    Lipton RB, Tepper SJ, Reuter U, Silberstein S, Stewart WF, Nilsen J, Leonardi DK, Desai P, Cheng S, Mikol DD, Lenz R.
    Neurology; 2019 May 07; 92(19):e2250-e2260. PubMed ID: 30996060
    [Abstract] [Full Text] [Related]

  • 22. Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety.
    Lattanzi S, Brigo F, Trinka E, Vernieri F, Corradetti T, Dobran M, Silvestrini M.
    Drugs; 2019 Mar 07; 79(4):417-431. PubMed ID: 30793254
    [Abstract] [Full Text] [Related]

  • 23. Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study.
    Wang SJ, Roxas AA, Saravia B, Kim BK, Chowdhury D, Riachi N, Tai MS, Tanprawate S, Ngoc TT, Zhao YJ, Mikol DD, Pandhi S, Wen S, Mondal S, Tenenbaum N, Hours-Zesiger P.
    Cephalalgia; 2021 Nov 07; 41(13):1285-1297. PubMed ID: 34171973
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. A Controlled Trial of Erenumab for Episodic Migraine.
    Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA.
    N Engl J Med; 2017 Nov 30; 377(22):2123-2132. PubMed ID: 29171821
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. A prospective real-world analysis of erenumab in refractory chronic migraine.
    Lambru G, Hill B, Murphy M, Tylova I, Andreou AP.
    J Headache Pain; 2020 Jun 01; 21(1):61. PubMed ID: 32487102
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Vascular safety of erenumab for migraine prevention.
    Kudrow D, Pascual J, Winner PK, Dodick DW, Tepper SJ, Reuter U, Hong F, Klatt J, Zhang F, Cheng S, Picard H, Eisele O, Wang J, Latham JN, Mikol DD.
    Neurology; 2020 Feb 04; 94(5):e497-e510. PubMed ID: 31852816
    [Abstract] [Full Text] [Related]

  • 34. A real-world, observational study of erenumab for migraine prevention in Canadian patients.
    Becker WJ, Spacey S, Leroux E, Giammarco R, Gladstone J, Christie S, Akaberi A, Power GS, Minhas JK, Mancini J, Rochdi D, Filiz A, Bastien N.
    Headache; 2022 Apr 04; 62(4):522-529. PubMed ID: 35403223
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study.
    Ashina M, Dodick D, Goadsby PJ, Reuter U, Silberstein S, Zhang F, Gage JR, Cheng S, Mikol DD, Lenz RA.
    Neurology; 2017 Sep 19; 89(12):1237-1243. PubMed ID: 28835404
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studies.
    Lipton RB, Dodick DW, Kudrow D, Reuter U, Tenenbaum N, Zhang F, Lima GPDS, Chou DE, Mikol DD.
    Cephalalgia; 2021 Dec 19; 41(14):1458-1466. PubMed ID: 34407654
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.